Jeffrey S Heier Selected Research

Macular Edema

9/2023	BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.
10/2022	The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study.
1/2022	INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.
9/2021	Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
1/2020	The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye.
12/2019	Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
2/2017	Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
11/2016	Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
11/2016	Vascular endothelial growth factor and diabetic macular edema.
2/2016	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey S Heier Research Topics

Disease

52	Macular Degeneration (Age-Related Maculopathy) 03/2024 - 11/2005
26	Macular Edema 09/2023 - 04/2005
11	Inflammation (Inflammations) 03/2024 - 04/2006
11	Retinal Vein Occlusion 09/2023 - 04/2005
10	Choroidal Neovascularization 05/2021 - 04/2006
9	Diabetic Retinopathy (Retinopathy, Diabetic) 10/2022 - 12/2012
8	Geographic Atrophy 10/2023 - 11/2008
7	Endophthalmitis (Ophthalmia) 01/2021 - 10/2006
5	Retinal Vasculitis 01/2023 - 11/2018
3	Retinal Perforations 01/2019 - 11/2013
3	Retinal Detachment (Retinal Detachments) 06/2016 - 02/2010
3	Cicatrix (Scar) 02/2010 - 11/2008
2	Eye Diseases (Eye Disease) 07/2024 - 10/2022
2	Neoplasms (Cancer) 03/2024 - 08/2016
2	Vascular Diseases (Vascular Disease) 01/2021 - 01/2020
2	Cataract (Cataracts) 11/2018 - 08/2010
2	Vision Disorders (Hemeralopia) 10/2018 - 11/2006
2	Vitreous Detachment (Posterior Vitreous Detachment) 01/2017 - 11/2013
2	Edema (Dropsy) 11/2016 - 01/2014
2	Proliferative Vitreoretinopathy 06/2016 - 02/2010
2	Stroke (Strokes) 03/2015 - 11/2006
2	Uveitis 10/2006 - 10/2006
1	Retinal Diseases 07/2024
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024
1	Melanoma (Melanoma, Malignant) 03/2024
1	Choroidal Effusions 03/2024
1	Disease Progression 10/2023
1	Confusion (Bewilderment) 01/2022
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2021
1	Vasculitis (Vasculitides) 11/2018
1	Plexiform Neurofibroma 01/2017
1	Fever (Fevers) 01/2017
1	vitreous floaters 01/2017
1	Microaneurysm 11/2016
1	Infections 01/2016
1	Myopia 01/2016
1	Pneumonia (Pneumonitis) 03/2015
1	Pain (Aches) 10/2014
1	Vitreous Hemorrhage 07/2014
1	Lens Subluxation 08/2010

Drug/Important Bio-Agent (IBA)

31	afliberceptIBA 03/2024 - 06/2011
29	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2024 - 04/2006
23	Ranibizumab (Lucentis)FDA Link 11/2016 - 04/2006
16	Retinaldehyde (Retinal)IBA 03/2024 - 11/2005
9	salicylhydroxamic acid (SHAM)IBA 10/2023 - 10/2006
7	Bevacizumab (Avastin)FDA Link 11/2016 - 11/2008
4	Proteins (Proteins, Gene)FDA Link 07/2024 - 04/2013
4	Angiopoietin-2IBA 07/2024 - 12/2021
4	faricimabIBA 02/2024 - 12/2021
4	brolucizumabIBA 01/2023 - 01/2021
4	Fluorescein (Funduscein)FDA LinkGeneric 05/2021 - 04/2012
3	pegcetacoplanIBA 10/2023 - 01/2020
3	Verteporfin (Visudyne)FDA Link 01/2009 - 10/2006
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2024 - 08/2016
2	PlacebosIBA 10/2023 - 10/2023
2	SteroidsIBA 01/2017 - 10/2014
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2009 - 11/2006
2	Monoclonal AntibodiesIBA 10/2006 - 10/2006
1	DEAE-Dextran (Pulsar)IBA 03/2024
1	Complement System Proteins (Complement)IBA 10/2023
1	Ophthalmic Solutions (Eye Drops)IBA 10/2022
1	IntegrinsIBA 10/2022
1	risuteganibIBA 01/2022
1	Neurofibromin 2 (Merlin)IBA 01/2022
1	Endothelial Growth FactorsIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Platelet-Derived Growth FactorIBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	AngiopoietinsIBA 01/2021
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	Complement C3 (C3 Complement)IBA 01/2020
1	KH902 fusion proteinIBA 01/2020
1	SolutionsIBA 11/2018
1	Vancomycin FDA LinkGeneric 11/2018
1	emixustatIBA 10/2018
1	AZD 6244IBA 01/2017
1	Mitogen-Activated Protein KinasesIBA 08/2016
1	binimetinibIBA 08/2016
1	AKB-9778IBA 03/2015
1	Class 3 Receptor-Like Protein Tyrosine PhosphatasesIBA 03/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2014
1	Genetic Markers (Genetic Marker)IBA 09/2013
1	MP0112IBA 04/2013
1	Designed Ankyrin Repeat ProteinsIBA 04/2013
1	tetrachloroisophthalonitrile (Bravo)IBA 04/2012
1	Ciliary Neurotrophic Factor (CNTF)IBA 04/2011

Therapy/Procedure

13	Injections 03/2024 - 04/2006
11	Lasers (Laser) 02/2017 - 04/2005
10	Therapeutics 03/2024 - 06/2009
6	Light Coagulation 02/2017 - 01/2014
6	Intravitreal Injections 10/2014 - 04/2006
5	Vitrectomy 03/2024 - 08/2010
3	Photochemotherapy (Photodynamic Therapy) 01/2009 - 10/2006
2	Intraocular Injections 01/2017 - 06/2010
2	Traction 01/2014 - 11/2013
2	Telescopes 11/2008 - 11/2006
1	Solid-State Lasers 01/2017
1	Aftercare (After-Treatment) 07/2014
1	Endoscopes 05/2014
1	Cataract Extraction 08/2010